Key clinical point: Pembrolizumab is a reasonable option for patients with advanced cervical cancer, especially those positive for PD-L1.
Major finding: Three PD-L1 patients had a complete response and nine had a partial response.
Study details: The prospective open-label study comprised 98 subjects.
Disclosures: Merck & Co. sponsored the study.
Chung HC et al. J Clin Oncol. 2019 April 3..